Breast cancer and its treatments (chemotherapy, radiotherapy, endocrine therapy) are associated with both systemic and localized inflammatory responses, marked by elevated levels of pro-inflammatory cytokines such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and C-reactive protein (CRP) [37]. This evidence concerns the gene IL6 and breast carcinoma.